Bristol-Myers Squibb and Pfizer announce randomized, controlled trial to evaluate the effect of atrial fibrillation screening on health outcomes in older individuals

The Bristol-Myers Squibb-Pfizer Alliance today announced the initiation of a new randomized, controlled study, GUARD-AF (ReducinG stroke by screening for UndiAgnosed atRial fibrillation in elderly inDividuals). The study seeks to determine if earlier detection of atrial fibrillation (AFib) through screening in previously undiagnosed men and women at least 70 years of age in the U.S. ultimately impacts the rate of stroke, compared to usual standard medical care.
Source: World Pharma News - Category: Pharmaceuticals Tags: Featured Bristol-Myers Squibb Business and Industry Source Type: news